Table 1.

Summary subject clinical data

	Age (y)	% male	Septal thickness (mm)	EF (%)	LVOT gradient (mmHg)
Controls (n=8)	56 ± 6	13	11.6 ± 0.8	64 ± 2	-
HCM patients
No sarcomere mutation (n=10)	49 ± 3	80	20.4 ± 0.9*	67 ± 2	73 ± 18
MYH7 mutations (n=8)	44 ± 6	50	18.3 ± 0.8	73 ± 4*	68 ± 8
MYBPC3 mutations (n=17)	39 ± 3*	41	28.0 ± 3.3*	75 ± 2*†	77 ± 11
Overall P-value	0.038		<0.001	0.006	0.9

^*P<0.05 vs controls

^†P<0.05 vs HCM patients with no sarcomere mutation